1. Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results. (February 2020) Authors: Lucas, K.J.; Lopez, P.; Lawitz, E.; Sheikh, A.; Aizenberg, D.; Hsia, S.; Bee, G.G. Boon; Vierling, J.; Frias, J.; White, J.; Eguchi, Y.; Lazas, D.; Neff, G.; Yoneda, M.; Augustin, S.; Kim, W.; Loeffler, Y.; Schaefer, F.; Lamle, S.; Martic, M. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 1 Page Start: e38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗